Option chain shows key data for Takeda Pharmaceutical Co's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Takeda Pharmaceutical Co.

Takeda Pharmaceutical Co (OTC:TKPHF) Stock, Option Chain

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Biotech

News

Health Care

Contracts

Small Cap

Movers

Trading Ideas

General

TBPH

TKPHF

In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties&#39; collaboration agreement with Theravance Biopharma Inc 

Takeda Moves Out From Licensing Agreement With Theravance Biopharma

Earnings

Guidance

Pre-Market Outlook

Takeda Pharmaceutical Co Ltd&#39;s (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its 

Takeda&#39;s FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues

Government

Media


	The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.


United Nations&#39; Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review

TAKEDA PHARM CO LTD ORD by Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co Ltd

Press Releases

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

TYO:4502

Takeda Pharmaceutical Co

Comments

Takeda Pharmaceutical Co

Takeda Pharmaceutical Co (TKPHF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga